KK2 - Reply to your last 2 posts. Last one first.

Assuming RVX208 passes all trials and becomes a drug the $2 billion is the lost revenue from the royalties from Zenith Capital Corp for the 3 year delay before getting it to market.

CCAA would surely happen. Eastern would own the IP up until the time the current LOC was written but not after. There has been a heck of a lot of IP written since this current LOC was arranged. There is or would be somewhere around $5 million in cash at the end of August. There is a lab worth around $20 million as well. The trustees in bankruptcy would follow the process set out in the act to allow the company the opportunity to find new investors to make good on outstanding debt to move the company forward. 

The process takes time. By the time the process is unravelled and the trial is re-filed and started again 3 years will pass (by my estimation). In that time, 3 years of  patent life will be completely lost and 3 years of royalty income to Zenith Capital will be gone. The 38% of that revenue that Eastern would otherwise have would be lost. My estimation of $2 billion is on the conservative side of the equation if this were to play out the way I have suggested. 

Since there seem to be some smart people involved here I don't really see any of this taking place anyways.

tada